Abstract
Microvascular damage and dysfunction represent the earliest morphological and functional markers of systemic sclerosis (SSc), a progressive connective tissue disease characterized by vascular abnormalities and diffuse fibrosis in the skin and internal organs. These early microvascular changes are clinically mirrored by Raynaud phenomenon, which can be primary (idiopathic) or secondary to several different conditions including SSc. Morphological and functional assessment of the cutaneous microvasculature have crucial implications for diagnosis, prognosis and therapy in SSc and secondary Raynaud phenomenon. Most importantly, imaging with nailfold videocapillaroscopy (NVC) enables the early differentiation between primary and secondary Raynaud phenomenon by identifying morphological patterns specific to various stages of SSc ('early', 'active' and 'late' patterns); the inclusion of these NVC patterns could increase the sensitivity of classification criteria for SSc. Findings on NVC are also markers of SSc severity and progression, as reduced capillary density has been associated with a high risk of developing digital skin ulcers and pulmonary arterial hypertension. Laser Doppler imaging and thermal imaging demonstrate the dysfunctional cutaneous blood flow in response to cold stimuli. Therapies targeting underlying vascular disease in SSc have been successfully designed to improve the symptoms of Raynaud phenomenon and to reduce ischemic injury to involved organs, and NVC patterns have been found to improve following targeted therapy; however, treatment of later fibrosis remains a challenge.
Key Points
-
Systemic sclerosis (SSc) is a complex systemic connective tissue disease characterized by vasculopathy and progressive involvement of the skin and internal organs with diffuse fibrosis
-
Raynaud phenomenon as a clinical marker of altered microvascular structure can be primary (idiopathic) or secondary to various conditions, in particular SSc
-
Nailfold videocapillaroscopy (NVC) represents the best and safest method to analyze microvascular abnormalities in SSc, and enables the early differential diagnosis between primary and secondary Raynaud phenomenon
-
The dysfunctional cutaneous blood flow in patients with both SSc and secondary RP in response to temperature stimuli have been demonstrated by use of laser Doppler imaging techniques
-
Reduced capillary density on NVC correlates with a high risk of developing digital skin ulcers and the presence of pulmonary arterial hypertension, and can therefore be used as a marker of SSc severity and progression
-
Therapies targeting underlying vascular disease in SSc improve symptoms of Raynaud phenomenon and reduce ischemic injury to involved tissue and organs; however, targeted treatment of fibrosis remains a challenge
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Black, C. M., Matucci-Cerinic, M. & Guillevin, L. Progress in systemic sclerosis: a 10-year perspective. Rheumatology (Oxford) 48 (Suppl. 3), iii1–iii2 (2009).
Bernatsky, S. et al. Scleroderma prevalence: demographic variations in a population-based sample. Arthritis Rheum. 61, 400–404 (2009).
Arias-Nuñez, M. C. et al. Systemic sclerosis in northwestern Spain: a 19-year epidemiologic study. Medicine (Baltimore) 87, 272–280 (2008).
Gabrielli, A., Avvedimento, E. V. & Krieg, T. Scleroderma. N. Engl. J. Med. 360, 1989–2003 (2009).
Abraham, D. J., Krieg, T., Distler, J. & Distler, O. Overview of pathogenesis of systemic sclerosis. Rheumatology (Oxford) 48 (Suppl. 3), iii3–iii7 (2009).
Herrick, A. L. Diagnosis and management of scleroderma peripheral vascular disease. Rheum. Dis. Clin. North Am. 34, 89–114 (2008).
Kahaleh, M. B. Raynaud phenomenon and the vascular disease in scleroderma. Curr. Opin. Rheumatol. 16, 718–722 (2004).
Herrick, A. L. Pathogenesis of Raynaud's phenomenon. Rheumatology (Oxford) 44, 587–596 (2005).
Leppert, J., Aberg, H., Ringqvist, I. & Sörensson, S. Raynaud's phenomenon in a female population: prevalence and association with other conditions. Angiology 38, 871–877 (1987).
Cutolo, M., Pizzorni, C. & Sulli, A. Identification of transition from primary Raynaud's phenomenon to secondary Raynaud's phenomenon by nailfold videocapillaroscopy. Arthritis Rheum. 56, 2102–2103 (2007).
Maricq, H. R., LeRoy, E. C. Patterns of finger capillary abnormalities in connective tissue disease by “widefield” microscopy. Arthritis Rheum. 16, 619–628 (1973).
Maricq, H. R., Weinberger, A. B. & LeRoy, E. C. Early detection of scleroderma-spectrum disorders by in vivo capillary microscopy. J. Rheumatol. 9, 289–291 (1982).
Cutolo, M., Grassi, W. & Matucci Cerinic, M. Raynaud's phenomenon and the role of capillaroscopy. Arthritis Rheum. 48, 3023–3030 (2003).
Hettema, M. E. et al. Decreased capillary permeability and capillary density in patients with systemic sclerosis using large-window sodium fluorescein videodensitometry of the ankle. Rheumatology (Oxford) 47, 1409–1412 (2008).
Brülisauer, M. & Bollinger, A. Measurement of different human microvascular dimensions by combination of videomicroscopy with Na-fluorescein (NaF) and indocyanine green (ICG) in normals and patients with systemic sclerosis. Int. J. Microcirc. Clin. Exp. 10, 21–31 (1991).
Murray, A. K. et al. Noninvasive imaging techniques in the assessment of scleroderma spectrum disorders. Arthritis Rheum. 61, 1103–1111 (2009).
Clark, S. et al. Comparison of thermography and laser Doppler imaging in the assessment of Raynaud's phenomenon. Microvasc. Res. 66, 73–76 (2003).
Cutolo, M., Sulli, A., Secchi, M. E., Olivieri, M. & Pizzorni, C. The contribution of capillaroscopy to the differential diagnosis of connective autoimmune diseases. Best Pract. Res. Clin. Rheumatol. 21, 1093–1108 (2007).
Cutolo, M., Pizzorni, C. & Sulli, A. Nailfold video-capillaroscopy in systemic sclerosis [German]. Z. Rheumatol. 63, 457–462 (2004).
Cutolo, M., Pizzorni, C., Secchi, M. E. & Sulli, A. Capillaroscopy. Best Pract. Res. Clin. Rheumatol. 22, 1093–1108 (2008).
De Angelis, R., Cutolo, M., Salaffi, F., Pablo Restrepo, J. & Grassi, W. Quantitative and qualitative assessment of one rheumatology trainee's experience with a self-teaching programme in videocapillaroscopy. Clin. Exp. Rheumatol. 27, 651–653 (2009).
De Angelis, R., Grassi, W. & Cutolo, M. A growing need for capillaroscopy in rheumatology. Arthritis Rheum. 61, 405–410 (2009).
Carpentier, P. H. & Maricq, H. R. Microvasculature in systemic sclerosis. Rheum. Dis. Clin. North Am. 16, 75–91 (1990).
Jayson, M. I. The micro-circulation in systemic sclerosis. Clin. Exp. Rheumatol. 2, 85–91 (1984).
Beyer, C., Schett, G., Gay, S., Distler, O. & Distler, J. H. Hypoxia in the pathogenesis of systemic sclerosis. Arthritis Res. Ther. 11, 220–227 (2009).
Maricq, H. R. et al. Diagnostic potential of in vivo capillary microscopy in scleroderma and related disorders. Arthritis Rheum. 23, 183–189 (1980).
Cutolo, M., Sulli, A., Pizzorni, C. & Accardo, S. Nailfold videocapillaroscopy assessment of microvascular damage in systemic sclerosis. J. Rheumatol. 27, 155–160 (2000).
Cutolo, M., Pizzorni, C. & Sulli, A. Capillaroscopy. Best Pract. Res. Clin. Rheumatol. 19, 437–452 (2005).
Caramaschi, P. et al. Scleroderma patients nailfold videocapillaroscopic patterns are associated with disease subset and disease severity. Rheumatology (Oxford) 46, 1566–1569 (2007).
Sulli, A., Secchi, M. E., Pizzorni, C. & Cutolo, M. Scoring the nailfold microvascular changes during the capillaroscopic analysis in systemic sclerosis patients. Ann. Rheum. Dis. 67, 885–887 (2008).
Smith, V. et al. Validation of the qualitative and semiquantitative assessment of the scleroderma spectrum patterns by nailfold videocapillaroscopy: preliminary results [abstract]. Arthritis Rheum. 60 (Suppl.), S164–S165 (2009).
Smith, V. et al. Reliability of the qualitative and semiquantitative nailfold videocapillaroscopy assessment in a systemic sclerosis cohort: a two-centre study. Ann. Rheum. Dis. 69, 1092–1096 (2010).
Cutolo, M. et al. Peripheral blood perfusion correlates with microvascular abnormalities in systemic sclerosis: a laser-Doppler and nailfold videocapillaroscopy study. J. Rheumatol. doi:10.3899/jrheum.091356.
Senecal, J. L., Henault, J. & Raymond, Y. The pathogenic role of autoantibodies to nuclear autoantigens in systemic sclerosis. J. Rheumatol. 32, 1643–1649 (2005).
Weiner, E. S. et al. Prognostic significance of anticentromere antibodies and anti-topoisomerase I antibodies in Raynaud's disease: a prospective study. Arthritis Rheum. 34, 68–77 (1991).
Cutolo, M. et al. Nailfold videocapillaroscopic patterns and serum autoantibodies in systemic sclerosis. Rheumatology (Oxford) 43, 719–726 (2004).
LeRoy, E. C. & Medsger, T. A. Jr. Criteria for the classification of early systemic sclerosis. J. Rheumatol. 28, 1573–1576 (2001).
Koenig, M. et al. Autoantibodies and microvascular damage are independent predictive factors for the progression of Raynaud's phenomenon to systemic sclerosis: a twenty-year prospective study of 586 patients, with validation of proposed criteria for early systemic sclerosis. Arthritis Rheum. 58, 3902–3912 (2008).
Steen, V., Denton, C. P., Pope, J. E. & Matucci-Cerinic, M. Digital ulcers: overt vascular disease in systemic sclerosis. Rheumatology (Oxford) 48 (Suppl. 3), iii19–iii24 (2009).
Cutolo, M., Sulli, A., Secchi, M. E. & Pizzorni, C. Capillaroscopy and rheumatic diseases: state of the art [German]. Z. Rheumatol. 65, 290–296 (2006).
Alivernini, S. et al. Skin ulcers in systemicsclerosis: determinants of presence and predictive factors of healing. J. Am. Acad. Dermatol. 60, 426–435 (2009).
Sebastiani, M. et al. Capillaroscopic skin ulcer risk index: a new prognostic tool for digital skin ulcer development in systemic sclerosis patients. Arthritis Rheum. 61, 688–694 (2009).
Secchi, M. E., Sulli, A., Pizzorni, C. & Cutolo, M. Nailfold capillaroscopy and blood flow laser-doppler analysis of the microvascular damage in systemic sclerosis: preliminary results [Italian]. Reumatismo 61, 34–40 (2009).
Caramaschi, P. et al. A score of risk factors associated with ischemic digital ulcers in patients affected by systemic sclerosis treated with iloprost. Clin. Rheumatol. 28, 807–813 (2009).
Coghlan, J. G. & Handler, C. Connective tissue associated pulmonary arterial hypertension. Lupus 15, 138–142 (2006).
Mukerjee, D. et al. Prevalence and outcome in systemic sclerosis associated pulmonary arterial hypertension: application of a registry approach. Ann. Rheum. Dis. 62, 1088–1093 (2003).
Hofstee, H. M. et al. Nailfold capillary density is associated with the presence and severity of pulmonary arterial hypertension in systemic sclerosis. Ann. Rheum. Dis. 68, 191–195 (2009).
Filaci, G. et al. Long-term treatment of patients affected by systemic sclerosis with cyclosporin A. Rheumatology (Oxford) 40, 1431–1432 (2001).
Filaci, G. et al. Cyclosporin A and iloprost treatment of systemic sclerosis: clinical results and interleukin-6 serum changes after 12 months of therapy. Rheumatology (Oxford) 38, 992–996 (1999).
Smith, V. et al. Rituximab in diffuse cutaneous systemic sclerosis: an open-label clinical and histopathological study. Ann. Rheum. Dis. 69, 193–197 (2010).
Lafyatis, R. et al. B cell depletion with rituximab in patients with diffuse cutaneous systemic sclerosis. Arthritis Rheum. 60, 578–683 (2009).
Quillinan, N. P. & Denton, C. P. Disease-modifying treatment in systemic sclerosis: current status. Curr. Opin. Rheumatol. 21, 636–641 (2009).
van Laar, J. M. & Tyndall, A. Cellular therapy of systemic sclerosis. Curr. Rheumatol. Rep. 10, 189–199 (2008).
Miniati, I. et al. Autologous stem cell transplantation improves microcirculation in systemic sclerosis. Ann. Rheum. Dis. 68, 94–98 (2009).
Henness, S. & Wigley, F. M. Current drug therapy for scleroderma and secondary Raynaud's phenomenon: evidence-based review. Curr. Opin. Rheumatol. 19, 611–618 (2007).
Gholam, P., Sehr, T., Enk, A. & Hartmann, M. Successful treatment of systemic-sclerosis-related digital ulcers with a selective endothelin type A receptor antagonist (sitaxentan). Dermatology 219, 171–173 (2009).
Moore, T. L., Vail, A. & Herrick, A. L. Assessment of digital vascular structure and function in response to bosentan in patients with systemic sclerosis-related Raynaud's phenomenon. Rheumatology (Oxford) 46, 363–364 (2007).
Brueckner, C. S. et al. Effect of Sildenafil on digital ulcers in systemic sclerosis—analysis from a single centre pilot study. Ann. Rheum. Dis. doi:10.1136/ard.2009.116475.
Hachulla, E., Launay, D. & Hatron, P. Y. Iloprost for the treatment of systemic sclerosis [French]. Presse Med. 37, 831–839 (2008).
Caramaschi, P. et al. Cyclophosphamide treatment improves microvessel damage in systemic sclerosis. Clin. Rheumatol. 28, 391–395 (2009).
Thompson, A. E., Shea, B., Welch, V., Fenlon, D. & Pope, J. E. Calcium-channel blockers for Raynaud's phenomenon in systemic sclerosis. Arthritis Rheum. 44, 1841–1847 (2001).
Gliddon, A. E. et al. Prevention of vascular damage in scleroderma and autoimmune Raynaud's phenomenon: a multicenter, randomized, double-blind, placebo-controlled trial of the angiotensin-converting enzyme inhibitor quinapril. Arthritis Rheum. 56, 3837–3846 (2007).
Sulli, A. et al. Raynaud's phenomenon and plasma endothelin: correlations with capillaroscopic patterns in systemic sclerosis. J. Rheumatol. 36, 1235–1239 (2009).
Dziadzio, M. et al. Losartan therapy for Raynaud's phenomenon and scleroderma: clinical and biochemical findings in a fifteen-week, randomized, parallel-group, controlled trial. Arthritis Rheum. 42, 2646–2655 (1999).
Herrick, A. L. Therapy: A local approach to Raynaud phenomenon. Nat. Rev. Rheumatol. 5, 246–247 (2009).
Anderson, M. E. et al. Digital vascular response to topical glyceryl trinitrate, as measured by laser Doppler imaging, in primary Raynaud's phenomenon and systemic sclerosis. Rheumatology (Oxford) 41, 324–348 (2002).
Kuwana, M., Okazaki, Y. & Kaburaki, J. Long-term beneficial effects of statins on vascular manifestations in patients with systemic sclerosis. Mod. Rheumatol. 19, 530–535 (2009).
Akhmetshina, A. et al. Treatment with imatinib prevents fibrosis in different preclinical models of systemic sclerosis and induces regression of established fibrosis. Arthritis Rheum. 60, 219–224 (2009).
Gabrielli, A. et al. Stimulatory autoantibodies to the PDGF receptor: a link to fibrosis in scleroderma and a pathway for novel therapeutic targets. Autoimmun. Rev. 7, 121–126 (2007).
Denton, C. P. et al. Recombinant human anti-transforming growth factor beta1 antibody therapy in systemic sclerosis: a multicenter, randomized, placebo-controlled phase I/II trial of CAT-192. Arthritis Rheum. 56, 323–333 (2007).
Varga, J. & Pasche, B. Transforming growth factor beta as a therapeutic target in systemic sclerosis. Nat. Rev. Rheumatol. 5, 200–206 (2009).
Cutolo, M. & Matucci Cerinic, M. Nailfold capillaroscopy and classification criteria for systemic sclerosis. Clin. Exp. Rheumatol. 25, 663–665 (2007).
Hudson, M. et al. Improving the sensitivity of the American College of Rheumatology classification criteria for systemic sclerosis. Clin. Exp. Rheumatol. 25, 754–757 (2007).
Matucci-Cerinic, M. et al. The challenge of early systemic sclerosis for the EULAR Scleroderma Trial and Research group (EUSTAR) community. It is time to cut the Gordian knot and develop a prevention or rescue strategy. Ann. Rheum. Dis. 68, 1377–1380 (2009).
Herrick, A. L. & Cutolo, M. Clinical implications from capillaroscopic analysis in patients with Raynaud's phenomenon and systemic sclerosis. Arthritis Rheum. doi:10.1002/art.27543.
Acknowledgements
Charles P. Vega, University of California, Irvine, CA, is the author of and is solely responsible for the content of the learning objectives, questions and answers of the MedscapeCME-accredited continuing medical education activity associated with this article.
Author information
Authors and Affiliations
Contributions
A. Sulli researched the data for the article. V. Smith and M. Cutolo provided substantial contributions to discussions of the content and reviewed and/or edited the manuscript before submission. M. Cutolo wrote the article.
Corresponding author
Ethics declarations
Competing interests
The authors declare no competing financial interests.
Rights and permissions
About this article
Cite this article
Cutolo, M., Sulli, A. & Smith, V. Assessing microvascular changes in systemic sclerosis diagnosis and management. Nat Rev Rheumatol 6, 578–587 (2010). https://doi.org/10.1038/nrrheum.2010.104
Published:
Issue Date:
DOI: https://doi.org/10.1038/nrrheum.2010.104
This article is cited by
-
Detection of microvascular changes in systemic sclerosis and other rheumatic diseases
Nature Reviews Rheumatology (2021)
-
Peripheral microcirculatory abnormalities are associated with cardiovascular risk in systemic sclerosis: a nailfold video capillaroscopy study
Clinical Rheumatology (2021)
-
Microangiopathy and forearm arterial blood flow in systemic sclerosis: a controlled study
Clinical Rheumatology (2020)
-
Is there a role for laser speckle contrast analysis (LASCA) in predicting the outcome of digital ulcers in patients with systemic sclerosis?
Clinical Rheumatology (2020)
-
Position article and guidelines 2018 recommendations of the Brazilian Society of Rheumatology for the indication, interpretation and performance of nailfold capillaroscopy
Advances in Rheumatology (2019)